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BIOLOGICS REGISTRY
V. Rivera Teran1, D. Alpizar-Rodriguez1, S. Sicsik2, F. Irazoque-Palazuelos2, 
D. Miranda2, D. Vega-Morales2, J. C. Casasola2, S. Carrilo2, A. Castillo2, 
S. Duran Barragan2, O. Muñoz2, A. Paz2, A. Peña2, A. Torres2, D. X. Xibille 
Friedmann2, A. Ramos2, J. F. Moctezuma2, F. Aceves2, E. Torres2, N. Santana2, 
M. Vazquez2, E. Zamora2, F. Guerrero2, C. Zepeda2, M. Rivera2, K. Alvarado2, 
C. F. Pacheco Tena2. 1Colegio Mexicano de Reumatología, Unidad de 
Investigación, Mexico City, Mexico; 2Colegio Mexicano de Reumatología, 
Mexico City, Mexico
Background: Most autoimmune diseases are more prevalent in women. Symp-
tom severity, disease progression, response to therapy and overall survival differ 
between males and females with rheumatic diseases.
Objectives: To identify the characteristics of autoimmune diseases presentation 
and treatment between male and female population using information from the 
Mexican Adverse Events Registry (BIOBADAMEX).
Methods: BIOBADAMEX is a Mexican ongoing cohort that collects the infor-
mation of patients using biologic and biosimilar drugs since 2016. For this 
study we included all patients enrolled in the registry and compared base-
line clinical and disease characteristics, treatment and presence of adverse 
events between genders. We used logistic regression to analyze univariable 
associations.







Age, median (IQR) 53 (44-60) 47 (34-55) 1.02 (1.0-1.1)*
Body Mass Index, median (IQR) 27 (23-31) 26 (23-30) 1.0 (0.9-1.1)
Smoking, n(%) 28 (5) 18 (16) 0.3 (0.2- 0.6)*
Disease duration, median (IQR) 9 (4-16) 7 (2-13) 1.0 (1.0-1.1)*
Diagnosis, n(%):    
 RA 414 (78) 37 (30) 2.4 (1.0-5.7)*
 AIJ 12 (2) 5 (4) 0.5 (0.1-1.9)
 AS 37 (7) 56 (46) 0.1 (0.1-0.4)*
 PsA 19 (4) 15 (12) 0.3 (0.1-0.8)*
 SLE 17 (3) 3 (2) 1.2 (0.3-5.2)
 Others 33 (6) 7 (6) 1
Disease Activity indexes, median (IQR)    
 DAS28a 4.9 (3.6-5.9) 4.9 (3.0-5.9) 1.1 (0.9-1.3)
 BASDAIb 4.8 (2.9-8) 5.3 (2.8-7.5) 0.9 (0.8- 1.1)
 ASDASc 3.2 (1.9-4.5) 3.9 (2.5-4.7) 0.8 (0.6-1.2)
 SLEDAId 14.5 (5.0-19.5) 25 (25.0-31.0) 0.6 (0.4-1.1)
High blood pressure, n(%) 77 (15) 14 (12) 1.3 (0.7-2.4)
Diabetes mellitus, n(%) 46 (9) 7 (6) 1.5 (0.7-3.5)
High cholesterol, n(%) 41 (8) 8 (7) 1.2 (0.4-2.6)
Other comorbidities, n(%): 173 (33) 26 (21) 1.8 (1.1 -2.8)*
Use of previous biologic, n(%): 216 (40) 44 (36) 1.2 (0.8- 1.8)
Use of steroids, n(%): 215 (42) 34 (29) 1.7 (1.1 -2.7)*
Use of DMARD, n(%): 418 (79) 89 (72) 1.4 (0.9-2.2)
Adverse eventsb, n(%): 69 (13) 14 (11) 1.2 (0.7-2.1)
 Severeb, n(%): 12 (17) 3 (21) 0.8 (0.2-3.1)
Univariable logistic regression analysis. *p<0.05. an=469, bn=99, cn=71, dn=19,
Results: A total of 655 participants were analysed, of which 82% were female 
(Table 1). We found women were older with a median of 53 years compared to 46 
years in men (OR 1.02, CI 1.0-1.1). Smoking was higher in men (16%) compared 
to women (5%), (OR 0.3, CI 0.2-0.6). Women had longer disease duration, 9 years 
compared to 7 years in men (OR 1, CI 1.0-1.1). Rheumatoid arthritis (RA) was more 
prevalent in women (OR 2.7, CI 1-6.9), while ankylosing spondylitis (AS) and psori-
atic arthritis (PsA) were more prevalent in men (OR 0.2, CI 0.1-0.4, and OR 0.3, CI 
0.1-0.9 respectively). Women had more comorbidities than men (OR 1.8, CI 1.1-2.8) 
and used steroids more frequently (OR 1.7, CI 1.1-2.7). Differences in disease activity 
were not found, however we noticed high activity scores among participants.
Conclusion: In our study we found sex differences regarding age and disease dura-
tion, being higher in women. As expected, the prevalence of RA was higher in women 
and AS and PsA in men. Overall, women used more steroids than men. An interesting 
finding was that patients had high disease activity. Future longitudinal analyses will 
allow us to analyse sex differences in disease progression and treatment response.
References: 
[1] Ortona E et al. Ann Ist Super Sanita 2016;52(2):205-12
[2] Ngo ST et al. Front Neuroendocrinol 2014;3(3):347-69
Disclosure of Interests: Vijaya Rivera Teran: None declared, Deshire 
Alpizar-Rodriguez: None declared, Sandra Sicsik: None declared, Fedra Irazo-
que-Palazuelos Consultant of: Bristol-Myers Squibb, Janssen, Pfizer Inc, Roche 
and UCB, Dafhne Miranda: None declared, David Vega-Morales: None declared, 
Julio Cesar Casasola: None declared, Sandra Carrilo: None declared, angel cas-
tillo: None declared, Sergio Duran Barragan: None declared, Omar Muñoz: None 
declared, Aleni Paz: None declared, Angélica Peña: None declared, Alfonso Tor-
res: None declared, Daniel Xavier Xibille Friedmann Consultant of: Lilly, Abbvie, 
Speakers bureau: Lilly, Abbvie, Azucena Ramos: None declared, José Francisco 
Moctezuma: None declared, Francisco Aceves: None declared, Estefania Tor-
res: None declared, Natalia Santana: None declared, Miguel Vazquez: None 
declared, Erick Zamora: None declared, Francisco Guerrero: None declared, 
Claudia Zepeda: None declared, Melanea Rivera: None declared, Kitzia Alva-
rado: None declared, Cesar Francisco Pacheco Tena: None declared
DOI: 10.1136/annrheumdis-2020-eular.6091
FRI0547 THE EFFECT OF CORRECTED INFLAMMATION, 
OXIDATIVE STRESS AND ENDOTHELIAL 
DYSFUNCTION ON FMD LEVELS IN PATIENTS 
WITH SELECTED CHRONIC DISEASES: A QUASI-
EXPERIMENTAL STUDY
M. Yilmaz1, M. Romano2, M. K. Basarali3, A. Elzagallaai4, M. Karaman1, 
Z. Demir1, M. F. Demir1, M. Seyrek5, F. Akcay1, N. Haksever6, D. Piskin4, 
R. Cimaz2, M. Rieder4, E. Demirkaya4. 1Epigenetic Health Solutions, Ankara, 
Turkey; 2Istituto Ortopedico Gaetano Pini, Milano, Italy; 3Ankara Provincial Health 
Directorate, Ankara, Turkey; 4Western University, London, Canada; 5Medisante 
Health Clinic, Ankara, Turkey; 6Yeditepe University, Istanbul, Turkey
Background: While the pathophysiology of chronic disorders varies there are 
three basic mechanisms - inflammation, oxidative stress and endothelial dys-
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which have a dynamic structure, are key to homeostasis. However, the failure 
of these mechanisms to work synchronously can lead to morbidity complicating 
the course of many chronic diseases.
Objectives: To evaluate the effect of anti-atherosclerotic liquid (AAL), anti-in-
flammatory capsules (AIC) and anti-oxidant liquid (AOL) supplementation on the 
flow-mediated dilatation (FMD), inflammatory, oxidative stress and endothelial 
dysfunction markers in patients with selected chronic diseases
Methods: We analyzed data of 178 patients from cohorts with selected chronic 
diseases (Rheumatoid arthritis, familial Mediterranean fever, DM type-2, Hyper-
tension, Multiple sclerosis, Chronic obstructive pulmonary disease, Alzheimer 
disease and Cancer) in this quasi-experimental study. Endothelial dysfunction 
was determined by FMD and serum asymmetric dimethylarginine (ADMA) levels. 
Serum ADMA, high sensitive C-reactive protein (hs-CRP), serum PTX3, malond-
ialdehyde (MDA), Cu/Zn-superoxide dismutase (Cu/Zn-SOD), glutathione perox-
idase (GSH-Px) levels and FMD were studied in baseline and after 12 weeks of 
Morinda citrifolia (AAL, 3 ml once per day), omega-3 (AIC, 3 capsules once per 
day) and extract with Alaskan blueberry and 21 different red purple fruit vegeta-
bles (AOL, 30 ml once per day). Stepwise multivariate regression analysis evalu-
ated the association of FMD with clinical and serologic parameters.
Results: Serum ADMA, MDA, PTX3, hsCRP and albumin levels, and proteinu-
ria were significantly decreased and CuZn-SOD, GSH-Px and FMD levels were 
significantly increased following AAL, AIC and AOL therapies. FMD was nega-
tively correlated with serum ADMA, MDA, PTX3, hsCRP levels, SBP and DBP 
and positively correlated to CuZn-SOD and eGFR levels both at baseline and 
after the 12-weeks treatment period. Multivariate regression analysis revealed 
that ADMA and PTX3 levels were independently related to FMD both before and 
after AAL, AIC and AOL therapies (Table 1, Figure 1).
Conclusion: Our study shows that serum ADMA, MDA, PTX3 levels are asso-
ciated with endothelial dysfunction in patients with selected chronic diseases. 
Short-term AAL, AIC and AOL therapies significantly improves FMD and normal-
izes ADMA, PTX3, hsCRP and MDA. This may have implications for adjunctive 
therapy in a number of chronic disorders.
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Background: Immune checkpoint inhibitors (ICIs) have improved cancer ther-
apy and especially clinical outcomes for patients with many malignancies [1]. ICIs 
lead to a higher immune system activity and subsequent attack of tumor cells. 
However, this effect can cause rheumatological immune related adverse events 
(rh-irAE), which have not yet been extensively studied.
Objectives: To determine the prevalence and type of rh-irAE in patients treated 
with ICIs. Additionally, our study focused on duration, severity and therapy of 
rh-irAE as well as the correlation between tumor response rate and patients with 
or without rh-irAE.
Methods: We analysed 437 patients between January 2014 and October 2019, 
treated with ipilimumab (anti-CTLA-4) and/ or nivolumab (anti-PD-1) or pembroli-
zumab (anti-PD-1) at the Department of Oncology, Hematology and Rheumatol-
ogy at the University Hospital in Bonn, Germany.
Results: Of the 437 patients, 260 (60%) were males, 177 (40%) were females 
with a mean age of 64 years (SD ± 14) at the beginning of the ICI-therapy. 152 
patients (34.8%) displayed at least one irAE.
We identified 20 patients (4.6%) with a minimum of one rh-irAE due to ICI-ther-
apy, seven of those had a pre-existing rheumatological disease. Those 20 
patients were initially treated for melanoma, lung cancer, head and neck tumor 
and gastrointestinal carcinoma. Rh-irAE occurred in one patient (2.6%) with ipil-
imumab, in nine patients (4.8%) with nivolumab, in nine patients (5.7%) with 
pembrolizumab and in one patient (1.9%) with a combination of ipilimumab and 
nivolumab.
Arthralgia developed most frequently in nine of the 20 patients (45%). Arthritis 
and myositis occurred with equal frequencies, in three cases each (3 patients, 
15%). Furthermore, three of the 20 patients (15%) developed a psoriatic arthritis 
and one patient (5%) osteoarthritis. The time to the first rh-irAE after exposure to 
ICIs was in median 100 days (IQR 45 – 406 days). Most rh-irAE were classified 
as moderate severe (CTCAE [Common Terminology Criteria of Adverse Events] 
grade 2: 55%).
15 patients (75%) were treated with systemic corticosteroids. In three cases 
(15%) additional therapy with methotrexate and in one patient (5%) with 
 tocilizumab was required. Other therapies including non-steroidal anti-in-
flammatory drugs and opioids were also used in eight patients. Even though 
patients benefited from ICI treatment, therapy had to be discontinued in nine 
of them (45%).
Interestingly, patients with rh-irAE had a significantly higher tumor response rate 
compared to patients without any irAE (95% vs. 33%; p<0,0001).
Conclusion: Our results show, that rh-irAE occur under ICI-therapy and in 
patients with higher tumor response. However, they are not the most frequent 
irAE after ICI exposure: 10.2% of all irAE were rheumatological (22 rh-irAE cases 
in 20 patients of a total of 216 irAE cases in 152 patients). As the use of ICIs is 
increasing for different malignancies the incidence of rh-irAE can be expected 
to increase.
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Table 1. Analysis of association between change (∆) in FMD and relevant 





∆ FMD (%) (r2=0.30)
Change
  
ADMA (µmol/l) -0.63 (<0.001) -0.25 (0.01)
MDA (nmol/ml) -0.58 (<0.001) -0.18 (0.02)
SOD (U/ml) 0.48 (<0.001) NS
GSH (U/ml) 0.02 (0.75) NS
HOMA -0.21 (0.001) NS
eGFR (ml/min/ 1.73 m2) -0.03 (0.62) NS
hsCRP (mg/l) -0.45 (<0.001) NS
PTX3 (ng/ml) -0.49 (<0.001) -0.21 (0.01)
SBP (mmHg) -0.26 (<0.001) NS
DBP (mmHg) -0.11 (0.12) NS
Hemoglobin (g/dl) 0.07 (0.32) NS
Total Cholesterol (mg/dl) -0.05 (0.49) NS
Triglyceride (mg/dl) -0.11 (0.12) NS
LDL (mg/dl) -0.12 (0.07) NS
HDL (mg/dl) 0.02 (0.82) NS
HbA1c (%) -0.26 (<0.001) NS
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